Allocation policy for hepatocellular carcinoma in the MELD era: Room for improvement
Allocation policy for hepatocellular carcinoma in the MELD era: Room for improvement
复制标题
DOI：
10.1002/lt.21329
复制
发表时间：
2007-11-01
影响因子：
4.6
通讯作者：
Feng, Sandy
中科院分区：
文献类型：
--
作者：
Roayaie, Kayvan;Feng, Sandy
目前，肝移植是治疗仅限于肝脏的肝细胞癌的最佳治疗方法。为了充分利用有限的资源，以及有无肝细胞癌患者之间的有效竞争，必须制定一种分配策略，以确定适合于肝细胞癌移植的患者子集，以及他们相对于非肝细胞癌患者公平的等待名单优先顺序。根据终末期肝病(MELD)分配模型，候选肝细胞癌必须符合米兰标准(单个肿瘤
Currently, liver transplantation is the optimal cure for hepatocellular cancer (HCC) limited to the liver.The requisite use of a scarce resource and the effective "competition" between transplant candidates with and without HCC necessitates an allocation policy that defines the subset of HCC patients appropriate for transplantation and their equitable waiting-list prioritization relative to non-HCC patients. Under Model for End-Stage Liver Disease (MELD) allocation, HCC candidates must meet the Milan criteria (single tumor